Evidence map›Paper›PMID 38877861›Full record

ArticleCurrent pharmaceutical design2025

An Integrative Network Pharmacology and Bioinformatics Approach for Deciphering the Multi-target Effect of

Nagaraja Sreeharsha, Girish Meravanige Basavarajappa, Bandar Aloufi, Predeepkumar Narayanappa Shiroorkar, Md Khalid Anwer, Abdur Rehman

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nagaraja SreeharshaDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
Girish Meravanige BasavarajappaDepartment of Biomedical Sciences, College of Medicine, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
Bandar AloufiDepartment of Biology, College of Science, University of Ha'il, Ha'il, Saudi Arabia.
Predeepkumar Narayanappa ShiroorkarDepartment of Biomedical Sciences, College of Medicine, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
Md Khalid AnwerDepartment of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Alkharj 11942, Saudi Arabia.
Abdur RehmanDepartment of Bioinformatics, College of Life Sciences, Northwest A&F University, Yangling, Shaanxi 712100, China.

Funding

Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia KFU241165
6 · The paper itself

Abstract

introductionThe COVID-19 pandemic represents a significant challenge across scientific, medical, and societal dimensions. The unpredictability of the disease progression, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), underscores the urgent need for identifying compounds that target multiple aspects of the virus to ensure swift and effective treatment.

methodsVarious

resultsThe results of molecular docking analysis indicated that

conclusionHowever, the findings were not validated in actual COVID-19 patients, so further investigation is needed to confirm the potential use of

Indexed as

Antiviral AgentsComputational BiologyCOVID-19 Drug TreatmentNetwork PharmacologyPlant ExtractsSARS-CoV-2COVID-19HumansMolecular Docking SimulationAntiviral AgentsPlant Extractsactive compoundsCOVID-19molecular docking simulation.multi-target approachnetwork pharmacologyNyctanthes arbortristis

Identifiers

PMID38877861

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.